Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, December 8, 2022. The pharmaceutical company Dicot announces that results from the latest study of the mechanism of action of LIB-01 have been selected to be presented at the European Society for Sexual Medicine's annual congress in February 2023.
The European Society for Sexual Medicine (ESSM) is the leading scientific society in sexual medicine and the annual congress in February brings together prominent researchers and clinicians from all over the world.
Dicot together with the partner Pelvipharm submitted an abstract with results from the latest study of the mechanism of action of LIB-01, i.e., how the drug works in the body to achieve the desired effect. The results show that the mechanism of action differs from today's potency drugs and that LIB-01 can thus represent a completely new generation of potency drugs.
The ESSM Scientific Council has now approved and selected Dicot's study results for presentation at the Annual Congress in Rotterdam in February 2023.
"For the second year in a row, ESSM handpicks our study results. That confirms the uniqueness of our drug candidate. The fact that our studies on the mechanism of action show that LIB-01 may come to represent a new generation of potency drugs, have a substantial news value in this medical field", says Elin Trampe, CEO at Dicot.